{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:35:37Z","timestamp":1769168137353,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ijaaonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.ijantimicag.2014.03.017","type":"journal-article","created":{"date-parts":[[2014,6,2]],"date-time":"2014-06-02T08:04:32Z","timestamp":1401696272000},"page":"131-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Long-term, low-dose erythromycin monotherapy for Mycobacterium avium complex lung disease: A propensity score analysis"],"prefix":"10.1016","volume":"44","author":[{"given":"Kosaku","family":"Komiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuyuki","family":"Kurashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Ihi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunji","family":"Mizunoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Kudoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ichi","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0005","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1440-1843.2008.01408.x","article-title":"When and how to treat pulmonary non-tuberculous mycobacterial diseases","volume":"14","author":"Thomson","year":"2009","journal-title":"Respirology"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0015","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1164\/rccm.201107-1203OC","article-title":"Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease","volume":"185","author":"Hayashi","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0020","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1164\/ajrccm.157.6.9710075","article-title":"Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin","volume":"157","author":"Kudoh","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0025","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1378\/chest.125.4.1239","article-title":"Clinical similarities and differences between human T-cell lymphotropic virus type 1-associated bronchiolitis and diffuse panbronchiolitis","volume":"125","author":"Kadota","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0030","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.pupt.2009.03.002","article-title":"Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis","volume":"22","author":"Florescu","year":"2009","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0035","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0040","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0045","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial","volume":"309","author":"Serisier","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0050","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/j.1365-2222.2012.03979.x","article-title":"Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments","volume":"42","author":"Cameron","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0055","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1128\/AAC.46.1.125-131.2002","article-title":"Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae","volume":"46","author":"Canu","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0060","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1128\/AAC.48.12.4624-4630.2004","article-title":"Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan","volume":"48","author":"Matsuoka","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0065","first-page":"251","article-title":"Lung disease caused by nontuberculous mycobacteria","volume":"16","author":"Alvarez-Uria","year":"2010","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0070","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1164\/rccm.201003-0503OC","article-title":"Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease","volume":"182","author":"Winthrop","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0075","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1378\/chest.12-0494","article-title":"Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M. avium complex lung disease","volume":"142","author":"Koh","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0080","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/thx.2009.114603","article-title":"Association between mycobacterial genotypes and disease progression in Mycobacterium avium pulmonary infection","volume":"64","author":"Kikuchi","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0085","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1128\/AAC.33.9.1531","article-title":"In vitro and in vivo activities of clarithromycin against Mycobacterium avium","volume":"33","author":"Fernandes","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0090","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1128\/AAC.33.9.1614","article-title":"In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex","volume":"33","author":"Naik","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0095","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1164\/rccm.201206-1088OC","article-title":"Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease","volume":"186","author":"Koh","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000195915","article-title":"Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis","volume":"58","author":"Nagai","year":"1991","journal-title":"Respiration"},{"issue":"Suppl. 9A","key":"10.1016\/j.ijantimicag.2014.03.017_bib0105","first-page":"12S","article-title":"Applying lessons learned in the treatment of diffuse panbronchiolitis to other chronic inflammatory diseases","volume":"117","author":"Kudoh","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0110","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1378\/chest.107.4.1035","article-title":"Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France","volume":"107","author":"Dautzenberg","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2014.03.017_bib0115","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","article-title":"Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease","volume":"174","author":"Griffith","year":"2006","journal-title":"Am J Respir Crit Care Med"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857914001423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857914001423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T14:53:55Z","timestamp":1538578435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857914001423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0924857914001423"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.03.017","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term, low-dose erythromycin monotherapy for Mycobacterium avium complex lung disease: A propensity score analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}